Aliqopa and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with Aliqopa (copanlisib).
Copanlisib Food/Lifestyle
Moderate Food Interaction
Grapefruit juice can increase the blood levels of copanlisib. This may increase side effects such as nausea, vomiting, diarrhea, mouth sores, high blood sugar, high blood pressure, lung or breathing problems, severe skin reactions, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should avoid the consumption of grapefruit and grapefruit juice during treatment with copanlisib. Talk to your doctor or pharmacist if you have questions on this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Switch to professional interaction data
Copanlisib High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
copanlisib - hypertension
Hypertension has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood pressure control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of hypertension. It is recommended to monitor blood pressure before and after the infusion with copanlisib.
Switch to professional interaction data
Aliqopa drug interactions
There are 343 drug interactions with Aliqopa (copanlisib).
Aliqopa disease interactions
There are 5 disease interactions with Aliqopa (copanlisib) which include:
More about Aliqopa (copanlisib)
- Aliqopa consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: PI3K inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi is used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is a CAR T-cell treatment used to treat relapsed or refractory large B-cell lymphoma ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.